APO Research
Talk to an analyst

APO RESEARCH · REPORT

Attenuated Vaccine for Human Rabies

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Attenuated Vaccine for Human Rabies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025197 pages

Choose your research edition.

Industry ResearchAttenuated Vaccine for Human Rabies Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Attenuated Vaccine for Human Rabies Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Attenuated Vaccine for Human Rabies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attenuated Vaccine for Human Rabies Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Attenuated Vaccine for Human Rabies Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Attenuated Vaccine for Human Rabies market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Attenuated Vaccine for Human Rabies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Attenuated Vaccine for Human Rabies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Attenuated Vaccine for Human Rabies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Attenuated Vaccine for Human Rabies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Attenuated Vaccine for Human Rabies include Changchun Zhuoyi Biological Co., Ltd, Wuhan Institute of Biological Products Co., Ltd, Shandong Yidu Biotechnology Co., Ltd, Ningbo Rongan Biopharmaceutical Co., Ltd, Liaoning Yisheng Biopharmaceutical Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd, Guangzhou Nuocheng Biological Products Co., Ltd, Chengdu Kanghua Biological Products Co., Ltd and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Attenuated Vaccine for Human Rabies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Attenuated Vaccine for Human Rabies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Attenuated Vaccine for Human Rabies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Attenuated Vaccine for Human Rabies market size, projected growth trends, production technologies, key applications, and end-use industries.

Attenuated Vaccine for Human Rabies Segment by Company

Changchun Zhuoyi Biological Co., Ltd

Wuhan Institute of Biological Products Co., Ltd

Shandong Yidu Biotechnology Co., Ltd

Ningbo Rongan Biopharmaceutical Co., Ltd

Liaoning Yisheng Biopharmaceutical Co., Ltd

Lanzhou Institute of Biological Products Co., Ltd

Guangzhou Nuocheng Biological Products Co., Ltd

Chengdu Kanghua Biological Products Co., Ltd

AstraZeneca

Sanofi Pasteur, Inc

Pfizer Inc

Novartis AG

Merck & Co Inc

GlaxoSmithKline

Cadila Pharmaceuticals Ltd

Attenuated Vaccine for Human Rabies Segment by Type

Vero Cell

Human Diploid Cell

Attenuated Vaccine for Human Rabies Segment by Application

Hospital

Clinic

Attenuated Vaccine for Human Rabies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attenuated Vaccine for Human Rabies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attenuated Vaccine for Human Rabies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attenuated Vaccine for Human Rabies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Attenuated Vaccine for Human Rabies market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Attenuated Vaccine for Human Rabies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Attenuated Vaccine for Human Rabies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Attenuated Vaccine for Human Rabies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Attenuated Vaccine for Human Rabies Industry Trends Table 2. Attenuated Vaccine for Human Rabies Industry Drivers Table 3. Attenuated Vaccine for Human Rabies Industry Opportunities and Challenges Table 4. Attenuated Vaccine for Human Rabies Industry Restraints Table 5. Global Attenuated Vaccine for Human Rabies Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Attenuated Vaccine for Human Rabies Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Attenuated Vaccine for Human Rabies Sales Market Share by Manufacturers Table 9. Global Attenuated Vaccine for Human Rabies Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Attenuated Vaccine for Human Rabies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Attenuated Vaccine for Human Rabies Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Attenuated Vaccine for Human Rabies Manufacturers, Product Type & Application Table 13. Global Attenuated Vaccine for Human Rabies Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Attenuated Vaccine for Human Rabies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Vero Cell Table 17. Major Manufacturers of Human Diploid Cell Table 18. Global Attenuated Vaccine for Human Rabies Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 20. Global Attenuated Vaccine for Human Rabies Sales by Type (2027-2032) & (K Units) Table 21. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2021-2026) Table 22. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2027-2032) Table 23. Global Attenuated Vaccine for Human Rabies Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Attenuated Vaccine for Human Rabies Revenue by Type (2021-2026) & (K Units) Table 25. Global Attenuated Vaccine for Human Rabies Revenue by Type (2027-2032) & (K Units) Table 26. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2021-2026) Table 27. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Global Attenuated Vaccine for Human Rabies Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 32. Global Attenuated Vaccine for Human Rabies Sales by Application (2027-2032) & (K Units) Table 33. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2021-2026) Table 34. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2027-2032) Table 35. Global Attenuated Vaccine for Human Rabies Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Attenuated Vaccine for Human Rabies Revenue by Application (2021-2026) & (K Units) Table 37. Global Attenuated Vaccine for Human Rabies Revenue by Application (2027-2032) & (K Units) Table 38. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2021-2026) Table 39. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2027-2032) Table 40. Global Attenuated Vaccine for Human Rabies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Attenuated Vaccine for Human Rabies Sales by Region (2021-2026) & (K Units) Table 42. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2021-2026) Table 43. Global Attenuated Vaccine for Human Rabies Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Attenuated Vaccine for Human Rabies Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Attenuated Vaccine for Human Rabies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 47. North America Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 48. Europe Attenuated Vaccine for Human Rabies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 50. Europe Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Attenuated Vaccine for Human Rabies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Attenuated Vaccine for Human Rabies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 57. Global Attenuated Vaccine for Human Rabies Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Attenuated Vaccine for Human Rabies Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Attenuated Vaccine for Human Rabies Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2021-2026) Table 61. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2027-2032) Table 62. Changchun Zhuoyi Biological Co., Ltd Company Information Table 63. Changchun Zhuoyi Biological Co., Ltd Business Overview Table 64. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 66. Changchun Zhuoyi Biological Co., Ltd Recent Development Table 67. Wuhan Institute of Biological Products Co., Ltd Company Information Table 68. Wuhan Institute of Biological Products Co., Ltd Business Overview Table 69. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 71. Wuhan Institute of Biological Products Co., Ltd Recent Development Table 72. Shandong Yidu Biotechnology Co., Ltd Company Information Table 73. Shandong Yidu Biotechnology Co., Ltd Business Overview Table 74. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 76. Shandong Yidu Biotechnology Co., Ltd Recent Development Table 77. Ningbo Rongan Biopharmaceutical Co., Ltd Company Information Table 78. Ningbo Rongan Biopharmaceutical Co., Ltd Business Overview Table 79. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 81. Ningbo Rongan Biopharmaceutical Co., Ltd Recent Development Table 82. Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information Table 83. Liaoning Yisheng Biopharmaceutical Co., Ltd Business Overview Table 84. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 86. Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Development Table 87. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 88. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 89. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 91. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 92. Guangzhou Nuocheng Biological Products Co., Ltd Company Information Table 93. Guangzhou Nuocheng Biological Products Co., Ltd Business Overview Table 94. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 96. Guangzhou Nuocheng Biological Products Co., Ltd Recent Development Table 97. Chengdu Kanghua Biological Products Co., Ltd Company Information Table 98. Chengdu Kanghua Biological Products Co., Ltd Business Overview Table 99. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 101. Chengdu Kanghua Biological Products Co., Ltd Recent Development Table 102. AstraZeneca Company Information Table 103. AstraZeneca Business Overview Table 104. AstraZeneca Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio Table 106. AstraZeneca Recent Development Table 107. Sanofi Pasteur, Inc Company Information Table 108. Sanofi Pasteur, Inc Business Overview Table 109. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 111. Sanofi Pasteur, Inc Recent Development Table 112. Pfizer Inc Company Information Table 113. Pfizer Inc Business Overview Table 114. Pfizer Inc Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 116. Pfizer Inc Recent Development Table 117. Novartis AG Company Information Table 118. Novartis AG Business Overview Table 119. Novartis AG Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio Table 121. Novartis AG Recent Development Table 122. Merck & Co Inc Company Information Table 123. Merck & Co Inc Business Overview Table 124. Merck & Co Inc Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 126. Merck & Co Inc Recent Development Table 127. GlaxoSmithKline Company Information Table 128. GlaxoSmithKline Business Overview Table 129. GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio Table 131. GlaxoSmithKline Recent Development Table 132. Cadila Pharmaceuticals Ltd Company Information Table 133. Cadila Pharmaceuticals Ltd Business Overview Table 134. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 136. Cadila Pharmaceuticals Ltd Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Attenuated Vaccine for Human Rabies Distributors List Table 140. Attenuated Vaccine for Human Rabies Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Attenuated Vaccine for Human Rabies Product Image Figure 2. Global Attenuated Vaccine for Human Rabies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Attenuated Vaccine for Human Rabies Market Size (2021-2032) & (US$ Million) Figure 4. Global Attenuated Vaccine for Human Rabies Sales (2021-2032) & (K Units) Figure 5. Global Attenuated Vaccine for Human Rabies Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Attenuated Vaccine for Human Rabies Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Vero Cell Image Figure 9. Human Diploid Cell Image Figure 10. Global Attenuated Vaccine for Human Rabies Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Attenuated Vaccine for Human Rabies Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2021-2032) Figure 13. Global Attenuated Vaccine for Human Rabies Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Attenuated Vaccine for Human Rabies Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Global Attenuated Vaccine for Human Rabies Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Attenuated Vaccine for Human Rabies Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2021-2032) Figure 21. Global Attenuated Vaccine for Human Rabies Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Attenuated Vaccine for Human Rabies Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2021-2032) Figure 24. North America Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2032) Figure 26. U.S. Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2032) Figure 31. Germany Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2032) Figure 38. China Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2032) Figure 46. Brazil Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Attenuated Vaccine for Human Rabies Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Attenuated Vaccine for Human Rabies Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Figure 57. North America Attenuated Vaccine for Human Rabies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Figure 59. Europe Attenuated Vaccine for Human Rabies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Attenuated Vaccine for Human Rabies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Attenuated Vaccine for Human Rabies Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Attenuated Vaccine for Human Rabies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Attenuated Vaccine for Human Rabies Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Attenuated Vaccine for Human Rabies Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Vero Cell
  • Human Diploid Cell
Applications
  • Hospital
  • Clinic
Companies covered
  • Changchun Zhuoyi Biological Co., Ltd
  • Wuhan Institute of Biological Products Co., Ltd
  • Shandong Yidu Biotechnology Co., Ltd
  • Ningbo Rongan Biopharmaceutical Co., Ltd
  • Liaoning Yisheng Biopharmaceutical Co., Ltd
  • Lanzhou Institute of Biological Products Co., Ltd
  • Guangzhou Nuocheng Biological Products Co., Ltd
  • Chengdu Kanghua Biological Products Co., Ltd
  • AstraZeneca
  • Sanofi Pasteur, Inc
  • Pfizer Inc
  • Novartis AG
  • Merck & Co Inc
  • GlaxoSmithKline
  • Cadila Pharmaceuticals Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Attenuated Vaccine for Human Rabies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Attenuated Vaccine for Human Rabies Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Attenuated Vaccine for Human Rabies Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Attenuated Vaccine for Human Rabies Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Attenuated Vaccine for Human Rabies Market Dynamics
  1. 2.1 Attenuated Vaccine for Human Rabies Industry Trends
  2. 2.2 Attenuated Vaccine for Human Rabies Industry Drivers
  3. 2.3 Attenuated Vaccine for Human Rabies Industry Opportunities and Challenges
  4. 2.4 Attenuated Vaccine for Human Rabies Industry Restraints
3 Attenuated Vaccine for Human Rabies Market by Manufacturers
  1. 3.1 Global Attenuated Vaccine for Human Rabies Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Attenuated Vaccine for Human Rabies Sales by Manufacturers (2021-2026)
  3. 3.3 Global Attenuated Vaccine for Human Rabies Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Attenuated Vaccine for Human Rabies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Attenuated Vaccine for Human Rabies Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Attenuated Vaccine for Human Rabies Manufacturers, Product Type & Application
  7. 3.7 Global Attenuated Vaccine for Human Rabies Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Attenuated Vaccine for Human Rabies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Attenuated Vaccine for Human Rabies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Attenuated Vaccine for Human Rabies Tier 1, Tier 2, and Tier 3
4 Attenuated Vaccine for Human Rabies Market by Type
  1. 4.1 Attenuated Vaccine for Human Rabies Type Introduction
  2. 4.1.1 Vero Cell
  3. 4.1.2 Human Diploid Cell
  4. 4.2 Global Attenuated Vaccine for Human Rabies Sales by Type
  5. 4.2.1 Global Attenuated Vaccine for Human Rabies Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Attenuated Vaccine for Human Rabies Sales by Type (2021-2032)
  7. 4.2.3 Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2021-2032)
  8. 4.3 Global Attenuated Vaccine for Human Rabies Revenue by Type
  9. 4.3.1 Global Attenuated Vaccine for Human Rabies Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Attenuated Vaccine for Human Rabies Revenue by Type (2021-2032)
  11. 4.3.3 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2021-2032)
5 Attenuated Vaccine for Human Rabies Market by Application
  1. 5.1 Attenuated Vaccine for Human Rabies Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Attenuated Vaccine for Human Rabies Sales by Application
  5. 5.2.1 Global Attenuated Vaccine for Human Rabies Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Attenuated Vaccine for Human Rabies Sales by Application (2021-2032)
  7. 5.2.3 Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2021-2032)
  8. 5.3 Global Attenuated Vaccine for Human Rabies Revenue by Application
  9. 5.3.1 Global Attenuated Vaccine for Human Rabies Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Attenuated Vaccine for Human Rabies Revenue by Application (2021-2032)
  11. 5.3.3 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2021-2032)
6 Global Attenuated Vaccine for Human Rabies Sales by Region
  1. 6.1 Global Attenuated Vaccine for Human Rabies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Attenuated Vaccine for Human Rabies Sales by Region (2021-2032)
  3. 6.2.1 Global Attenuated Vaccine for Human Rabies Sales by Region (2021-2026)
  4. 6.2.2 Global Attenuated Vaccine for Human Rabies Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Attenuated Vaccine for Human Rabies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Attenuated Vaccine for Human Rabies Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Attenuated Vaccine for Human Rabies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Attenuated Vaccine for Human Rabies Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Attenuated Vaccine for Human Rabies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Attenuated Vaccine for Human Rabies Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Attenuated Vaccine for Human Rabies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Attenuated Vaccine for Human Rabies Revenue by Region
  1. 7.1 Global Attenuated Vaccine for Human Rabies Revenue by Region
  2. 7.1.1 Global Attenuated Vaccine for Human Rabies Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Attenuated Vaccine for Human Rabies Revenue by Region (2021-2026)
  4. 7.1.3 Global Attenuated Vaccine for Human Rabies Revenue by Region (2027-2032)
  5. 7.1.4 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Attenuated Vaccine for Human Rabies Revenue (2021-2032)
  8. 7.2.2 North America Attenuated Vaccine for Human Rabies Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Attenuated Vaccine for Human Rabies Revenue (2021-2032)
  11. 7.3.2 Europe Attenuated Vaccine for Human Rabies Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Attenuated Vaccine for Human Rabies Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Attenuated Vaccine for Human Rabies Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Attenuated Vaccine for Human Rabies Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Attenuated Vaccine for Human Rabies Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Changchun Zhuoyi Biological Co., Ltd
  2. 8.1.1 Changchun Zhuoyi Biological Co., Ltd Company Information
  3. 8.1.2 Changchun Zhuoyi Biological Co., Ltd Business Overview
  4. 8.1.3 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  6. 8.1.5 Changchun Zhuoyi Biological Co., Ltd Recent Developments
  7. 8.2 Wuhan Institute of Biological Products Co., Ltd
  8. 8.2.1 Wuhan Institute of Biological Products Co., Ltd Company Information
  9. 8.2.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
  10. 8.2.3 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  12. 8.2.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
  13. 8.3 Shandong Yidu Biotechnology Co., Ltd
  14. 8.3.1 Shandong Yidu Biotechnology Co., Ltd Company Information
  15. 8.3.2 Shandong Yidu Biotechnology Co., Ltd Business Overview
  16. 8.3.3 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  18. 8.3.5 Shandong Yidu Biotechnology Co., Ltd Recent Developments
  19. 8.4 Ningbo Rongan Biopharmaceutical Co., Ltd
  20. 8.4.1 Ningbo Rongan Biopharmaceutical Co., Ltd Company Information
  21. 8.4.2 Ningbo Rongan Biopharmaceutical Co., Ltd Business Overview
  22. 8.4.3 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  24. 8.4.5 Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments
  25. 8.5 Liaoning Yisheng Biopharmaceutical Co., Ltd
  26. 8.5.1 Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information
  27. 8.5.2 Liaoning Yisheng Biopharmaceutical Co., Ltd Business Overview
  28. 8.5.3 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  30. 8.5.5 Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments
  31. 8.6 Lanzhou Institute of Biological Products Co., Ltd
  32. 8.6.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  33. 8.6.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  34. 8.6.3 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  36. 8.6.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  37. 8.7 Guangzhou Nuocheng Biological Products Co., Ltd
  38. 8.7.1 Guangzhou Nuocheng Biological Products Co., Ltd Company Information
  39. 8.7.2 Guangzhou Nuocheng Biological Products Co., Ltd Business Overview
  40. 8.7.3 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  42. 8.7.5 Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments
  43. 8.8 Chengdu Kanghua Biological Products Co., Ltd
  44. 8.8.1 Chengdu Kanghua Biological Products Co., Ltd Company Information
  45. 8.8.2 Chengdu Kanghua Biological Products Co., Ltd Business Overview
  46. 8.8.3 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  48. 8.8.5 Chengdu Kanghua Biological Products Co., Ltd Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 Sanofi Pasteur, Inc
  56. 8.10.1 Sanofi Pasteur, Inc Company Information
  57. 8.10.2 Sanofi Pasteur, Inc Business Overview
  58. 8.10.3 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio
  60. 8.10.5 Sanofi Pasteur, Inc Recent Developments
  61. 8.11 Pfizer Inc
  62. 8.11.1 Pfizer Inc Company Information
  63. 8.11.2 Pfizer Inc Business Overview
  64. 8.11.3 Pfizer Inc Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio
  66. 8.11.5 Pfizer Inc Recent Developments
  67. 8.12 Novartis AG
  68. 8.12.1 Novartis AG Company Information
  69. 8.12.2 Novartis AG Business Overview
  70. 8.12.3 Novartis AG Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio
  72. 8.12.5 Novartis AG Recent Developments
  73. 8.13 Merck & Co Inc
  74. 8.13.1 Merck & Co Inc Company Information
  75. 8.13.2 Merck & Co Inc Business Overview
  76. 8.13.3 Merck & Co Inc Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio
  78. 8.13.5 Merck & Co Inc Recent Developments
  79. 8.14 GlaxoSmithKline
  80. 8.14.1 GlaxoSmithKline Company Information
  81. 8.14.2 GlaxoSmithKline Business Overview
  82. 8.14.3 GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio
  84. 8.14.5 GlaxoSmithKline Recent Developments
  85. 8.15 Cadila Pharmaceuticals Ltd
  86. 8.15.1 Cadila Pharmaceuticals Ltd Company Information
  87. 8.15.2 Cadila Pharmaceuticals Ltd Business Overview
  88. 8.15.3 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  90. 8.15.5 Cadila Pharmaceuticals Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Attenuated Vaccine for Human Rabies Value Chain Analysis
  2. 9.1.1 Attenuated Vaccine for Human Rabies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Attenuated Vaccine for Human Rabies Production Mode & Process
  6. 9.2 Attenuated Vaccine for Human Rabies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Attenuated Vaccine for Human Rabies Distributors
  9. 9.2.3 Attenuated Vaccine for Human Rabies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst